COMMUNIQUÉS West-GlobeNewswire

Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026
Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, 2026 Industry expert [...]
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment Madrigal [...]
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
11/02/2026
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical [...]
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization [...]
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026
February 11, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and [...]
NTG Nordic Transport Group A/S - 2025 Annual Report Conference Call
11/02/2026
NTG Nordic Transport Group A/S – 2025 Annual Report Conference Call We expect to release the 2025 Annual Report of NTG Nordic Transport Group on the evening of March 4, 2026. A webcast and conference call will be held [...]
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will [...]
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
11/02/2026
WEST ORANGE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- InfiniHealth Medical Group today announced the continued advancement of its integrated multispecialty care model, a clinical framework that brings multiple board- [...]
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
11/02/2026
The appointment of former General Manager of Novo Nordisk UK follows the recent appointment of Professor Sir Jonathan Van-Tam to Reset Health’s Advisory Board LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the [...]
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
11/02/2026
Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy product Partnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 [...]
Galecto Announces Pricing of $275 Million Underwritten Public Offering
11/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
11/02/2026
TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Berlin Protocol Performance Enhancer Product Information Updated — What Do Consumers Consider When Researching Male Enhancement Supplement Options in 2026?
11/02/2026
An informational overview examining what consumers research about Berlin Protocol Performance Enhancer, ingredient transparency in the male enhancement supplement category, and what publicly available product [...]
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
10/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
10/02/2026
All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro [...]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
10/02/2026
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB [...]
DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et discutera de l'avenir de l'EPIT lors du congrès annuel 2026 de l'AAAAI
10/02/2026
Châtillon, France, le 10 février (22 :30 CET) 2026 DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et [...]
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
10/02/2026
Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment [...]
Galapagos Receives Transparency Notifications from Bank of America
10/02/2026
Mechelen, Belgium ; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation [...]

Pages